Innate Pharma SA Research and Development Expense
Innate Pharma SA (IPHA) reported Research and Development Expense of EUR 43.62 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-04-01.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:ResearchAndDevelopmentExpense · last filed 2026-04-01
| Period end | Research And Development Expense 6 month | Research And Development Expense 6 month as first filed | Research And Development Expense 12 month | Research And Development Expense 12 month as first filed |
|---|---|---|---|---|
| 2025-12-31 | 43.62M EUR 20-F · filed 2026-04-01 | |||
| 2025-06-30 | 20.52M EUR 6-K · filed 2025-09-17 | |||
| 2024-12-31 | 51.98M EUR 20-F · filed 2026-04-01 | |||
| 2024-06-30 | 29.08M EUR 6-K · filed 2025-09-17 | |||
| 2023-12-31 | 56.02M EUR 20-F · filed 2026-04-01 | |||
| 2023-06-30 | 31.45M EUR 6-K · filed 2024-09-12 | |||
| 2022-12-31 | 51.66M EUR 20-F · filed 2025-04-30 | |||
| 2022-06-30 | 24.96M EUR 6-K · filed 2023-09-14 | |||
| 2021-12-31 | 47.00M EUR 20-F · filed 2024-04-04 | |||
| 2021-06-30 | 21.21M EUR 6-K · filed 2022-09-15 | 21.79M EUR 6-K · filed 2021-09-15 | ||
| 2020-12-31 | 49.71M EUR 20-F · filed 2023-04-06 | 58.61M EUR 20-F · filed 2021-04-27 | ||
| 2020-06-30 | 31.50M EUR 6-K · filed 2021-09-15 | |||
| 2019-12-31 | 62.90M EUR 20-F · filed 2022-04-04 | 78.84M EUR 20-F · filed 2020-04-24 | ||
| 2018-12-31 | 69.56M EUR 20-F · filed 2021-04-27 | |||
| 2017-12-31 | 67.00M EUR 20-F · filed 2020-04-24 |